Taysha Gene Therapies, Inc. (TSHA) stock
TSHANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$4.00−0.06 (-1.48%)
Close on Nov 17, 2026Market cap $1.30BP/E –Yield –
Taysha Gene Therapies r&d expenses
Research and development expenses are spending on new products and technology.
Taysha Gene Therapies's R&D Expenses for the twelve months ending Jun 30, 2026 was $123.14M, up 86.6% year over year. For fiscal 2025 it was $86.40M, up 30.9% from the year before. The highest annual figure on record is $131.94M in fiscal 2021.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $86.40M | +30.9% |
| FY2024 | Dec 31, 2024 | $66.00M | +16.2% |
| FY2023 | Dec 31, 2023 | $56.78M | -37.7% |
| FY2022 | Dec 31, 2022 | $91.17M | -30.9% |
| FY2021 | Dec 31, 2021 | $131.94M | +313.7% |
| FY2020 | Dec 31, 2020 | $31.89M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $38.64M | +91.8% |
| Q1 FY2026 | Mar 31, 2026 | $33.81M | +117.2% |
| Q4 FY2025 | Dec 31, 2025 | $24.95M | +62.8% |
| Q3 FY2025 | Sep 30, 2025 | $25.75M | +72.3% |
| Q2 FY2025 | Jun 30, 2025 | $20.14M | +33.6% |
| Q1 FY2025 | Mar 31, 2025 | $15.57M | -24.7% |
| Q4 FY2024 | Dec 31, 2024 | $15.33M | +20.8% |
| Q3 FY2024 | Sep 30, 2024 | $14.95M | +26.8% |
| Q2 FY2024 | Jun 30, 2024 | $15.07M | -23.8% |
| Q1 FY2024 | Mar 31, 2024 | $20.66M | +65.1% |
| Q4 FY2023 | Dec 31, 2023 | $12.68M | -0.2% |
| Q3 FY2023 | Sep 30, 2023 | $11.79M | -29.7% |
| Q2 FY2023 | Jun 30, 2023 | $19.79M | -15.8% |
| Q1 FY2023 | Mar 31, 2023 | $12.51M | -67.2% |
| Q4 FY2022 | Dec 31, 2022 | $12.71M | -66.5% |
| Q3 FY2022 | Sep 30, 2022 | $16.77M | -57.6% |
| Q2 FY2022 | Jun 30, 2022 | $23.51M | -23.3% |
| Q1 FY2022 | Mar 31, 2022 | $38.18M | +60.1% |
| Q4 FY2021 | Dec 31, 2021 | $37.92M | +209.3% |
| Q3 FY2021 | Sep 30, 2021 | $39.53M | +257.5% |
| Q2 FY2021 | Jun 30, 2021 | $30.64M | +900.8% |
| Q1 FY2021 | Mar 31, 2021 | $23.85M | +332.6% |
| Q4 FY2020 | Dec 31, 2020 | $12.26M | +1142.1% |
| Q3 FY2020 | Sep 30, 2020 | $11.06M | – |
| Q2 FY2020 | Jun 30, 2020 | $3.06M | – |
| Q1 FY2020 | Mar 31, 2020 | $5.51M | – |
| Q4 FY2019 | Dec 31, 2019 | $987.00K | – |
See a number that looks wrong?